Latest News



March 29, 2018 0

Out-of-home advertising company, Brite Media Group, has acquired Mesmerize Marketing, a leader in patient education at the point-of-care. “Gregory Leibert, the founder and Chief Executive Officer of Mesmerize, and Craig Mait, Chief Operating Officer, will join Brite Media in leadership roles and will continue to operate the Mesmerize business along with their existing team,” outlined the news release.

With Mesmerize's “targeted educational materials including wallboards, literature distribution, branded medical essentials, and mobile integration to patients and care givers in waiting rooms, exam rooms, and other high traffic areas of doctors’ offices, dental offices, community-based organizations, AIDS service organizations, and independent pharmacies,” Brite Media now has strong access to the point-of-care space. In return, “[t]he partnership with Brite Media gives Mesmerize Marketing the resources necessary to scale our rapidly growing point-of-care networks,” said Leibert. “Mesmerize will also look to expand our patient education and deliver significant results to our customers, by supplementing our industry-leading static media presence with new static and digital media platforms.”

Michael Ellis, Brite Media’s President and Chief Operating Officer, added that “Mesmerize will perfectly complement Brite’s current media platforms.  The combined companies will leverage the strengths, creativity, and human capital of both businesses to continue delivering outstanding results to our customers.” Brite Media had been acquired by The Beekman Group in 2014. Since then, Brite Media “has more than doubled in size through organic growth and acquisitions led by Beekman and management.”

admin


March 29, 2018 0

Andrew Schirmer has taken on the role of Chief Executive Officer with Ogilvy CommonHealth North America, a WPP Health & Wellness company. He returns to his roots, having started his career with the company in 1987. Schirmer was most recently President with McCann Global Health, overseeing the firm's global and public health unit. According to the news release, he was “responsible for leading the work the agency did for UNICEF, the US government, the Bill & Melinda Gates Foundation and private sector organizations, and the groundbreaking ‘Immunity Charm' campaign, which tracks vaccinations on behalf of the Afghanistan Health Ministry, and for which the agency won a Grand Prix at Cannes Lions in 2017.”

Mike Hudnall, CEO of WPP Health & Wellness, stated in the news release: “Andrew exemplifies the values we hold dear: excellence in client partnership, support for our incredible people, and an unbridled passion for making the world a better and healthier place. His professionally diverse background in healthcare marketing, consumer wellness, and public health and policy positions him well to help accelerate OCH’s diversification and growth strategy moving forward. Andrew is a champion of great work and true visionary who will bring a human-centered leadership to OCH’s culture. I have complete confidence that Andrew is the right person to unlock the potential of our people and our business as we move forward.”

Schirmer will report directly to Hudnall and work closely with Marc Weiner, Ogilvy CommonHealth's COO; Darlene Dobry, managing partner; and Terry Cully, managing director in Canada. Schirmer fills the vacant CEO position after Matt Giegerich's departure in spring 2017. Giegerich founded his own company, Lucky 7 Consulting, before becoming CEO with Inception Companies, a leading provider of video production, interactive visual solutions, broadcast and webcast platforms for virtual meetings, and audio/visual support.

 

admin


March 23, 2018 0

Kantar Media reported full year 2017 DTC spending declined 4.6%. Is this decline any reason for concern among the DTC industry? No, not really. DTC spending has become an integral part of drug brand marketing. There is no drug industry talk of ending it or reducing its importance. There was such talk during the temporary decline of spending about five years ago but that never took hold.

Bob Ehrlich
“Growth in any given year will depend on new brand entries…”
-Bob Ehrlich

There were several CEOs then who were questioning whether DTC was hurting the drug industry in terms of image. There was joy among the critics that maybe drug companies would end the practice of creating consumer demand. I think the drug companies recognized that the critics would not change their negative views even if DTC was ended. The critics did not like drug companies before the 1997 spending surge and although DTC angered them more, that is not their biggest issue. It has been and is about price. Unless drug makers agree with critics they make obscene profits and cut their prices to generic levels; there will be no peace with the critics. If there were no DTC, price issues would remain. DTC is a convenient talking point and used by critics to lead the public to believe they are being manipulated by greedy drug makers.

So back to the decline of 4.6%. Kantar reported that magazines and Internet companies shouldered the whole decline. In fact television DTC was up over 6% in 2017. The print media industry has a selling job ahead to keep their publications profitable. This is not just about their share of drug ads but a fight for viability of traditional hard copy magazines. Print is still a place to see greater detail on drug benefits and risks and I expect the major print conglomerates to innovate to keep readers and advertisers.

DTC is now a mature ad category. Growth in any given year will depend on new brand entries and when brands are going off patent. We can therefore expect years with growth and years with decline. The 4.6% decline is not the start of any long term trend down. As long as drug companies see a positive ROI DTC ads will continue. We saw the rise of diabetes drug ads the past few years along with the end of erectile dysfunction ads as they go off patent. That is what we will continue to see in DTC spending with some categories accelerating and some ending their ads.

Of course there are existential threats to DTC which could make spending decline dramatically. Those include an outright ban, putting a moratorium on for new brands, taxing it by making it non-deductible, or going to single payer healthcare. None of these will happen in the next few years. That being said, a Democrat House and Senate majority could make it very possible that DTC will be a casualty of healthcare reform. Mr. Trump might sign a bill accepting limitations on DTC as part of a bigger bargain on free market practices.

In the meantime, we will see DTC remain strong in total and see spending shifts within media categories.

Certainly media innovators are looking at new digital platforms such as virtual medicine, point of care opportunities, and new ways to gain efficiency from television and print.

Bob Ehrlich


March 9, 2018 0

DTC Perspectives, the leading forum for direct-to-consumer (DTC) advertising thought leaders, will honor a dynamic group of pharmaceutical companies and brands at the much-anticipated DTC National Advertising Awards. The awards are part of the 18th Annual DTC National Conference held April 18-20 in Boston.

Sponsored by Health Monitor Network, the 2018 Advertising Awards showcase the best marketing and advertising across 22 categories, including a Voter’s Choice and Chairman’s Award categories. (Industry voting for the Voter’s Choice category will run in March. Stay tuned for details!) Gold, Silver, and Bronze winners will be announced during the Advertising Awards Dinner held on April 19.

“The DTC National is exciting each year for us as a celebration of the creativity and effectiveness of DTC consumer promotion,” says Ken Freirich, President of Health Monitor Network. “As an entrepreneurial company celebrating our 35th anniversary, developing creative solutions to facilitate patient and HCP dialogue, we are pleased to sponsor the awards and to recognize the many successes in the marketplace.”

[button link=”https://www.dtcperspectives.com/dtcn/2018-ad-awards/”]View the 2018 Finalists[/button]

admin


March 9, 2018 0

Alex Azar the new HHS Secretary has promised to make healthcare value a top goal. Azar says he will shake up the healthcare system to deliver value to patients. He delivered that message this week to hospital executives at a convention in Washington. Azar said that America is not getting enough for the money spent on health services.

In his speech he outlined ways he plans to encourage better bang for the buck. Azar wants patients to have control of their online health records so they are easier to access across providers. He also wants much greater price transparency so patients know how much they are spending. This is because patient deductibles and co-pays have risen so much that patients, not insurers, are the payers for much of their care. Azar said the fee for service model must change to encourage delivery of outcomes rather than just encourage more tests and procedures.

Bob Ehrlich
“It is likely we will see government…intercede on drug pricing.”
-Bob Ehrlich

Citing the Trump philosophy that shaking things up is necessary, Azar promised that innovation will be encouraged through the Medicare system. He vowed to remove regulation that impedes innovative approaches. Although he was talking to hospital executives, Azar said drug companies and doctors also must also deliver value.

Drug companies will be under intense pressure to justify the value of newer and often much more expensive treatments. From Azar’s speech and Trump’s past criticism of drug prices, it is likely we will see government be more willing to intercede on drug pricing. Whether that is through Medicare price negotiation, reimportation, or pressure on patents, it is clear drug companies will feel pressure.

What does all this mean for DTC? It makes it more likely drug companies will advertise branded drugs. They want to raise awareness among the public and doctors of new treatments. By doing so that keeps pressure on payers to cover the newer drugs that are generally much more expensive than older alternatives. While advertising drugs that cost $100k a year might annoy insurance companies it does force them to decide faster on formulary status. They have to respond to their consumer and physician base about why a life saving drug is not covered. Insurers are justified in demanding outcome research but it is hard to refuse covering a drug that extends the lives of patients, particularly if it is advertised widely.

What is clear is American consumers cannot keep paying higher premiums, deductibles, and co-pays that are well above their wage increases. That is not sustainable and the public will demand action. Azar saying a shake up will occur is not bluster. It has to happen or else the single payer advocates will get what they want, a government run healthcare system.

Bob Ehrlich


March 2, 2018 0

Alphabet, formerly known as Google, has decided to enter the health insurance business according to a CNBC report. The entry of big data companies into health insurance could have significant impact on costs. The Alphabet health subsidiary is called Verily. Why might big data companies affect costs of care?

They have tremendous capabilities to know their user base’s behavioral tendencies. That could lead to better analysis on how to improve communicating targeted health information. This capability is both on a group level and increasingly on an individual basis. Verily could have an enormous opportunity to effect change in terms of health behavior. Knowing us as they do, one can envision an automated outreach to help prevent and treat illness before it escalates into expensive hospital care.

Bob Ehrlich
“Verily could have an enormous opportunity…”
-Bob Ehrlich

Verily will likely try to work with existing insurers, both public and private, to use their data smarts to lower payer costs. This could be through better identification of populations to message needed health information or to provide individual outreach to individuals identified as high risk or non-compliant on treatment.

If it sounds like big brother watching over you, it is. We may eventually see Verily or another data giant like Amazon become your health advisor and remind you to take a diagnostic test, track your vital signs, analyze your DNA, find the best doctor, make your appointments, store your medical data, and potentially use algorithms to diagnose and offer treatment plans. One can envision an avatar of a doctor replacing the real doctor one day.

Verily is likely trying to make insurance cheaper and more widely available. Clearly, they have a huge financial incentive to enter the market where premiums have become too high for many Americans. I love to hear when innovative private companies are entering the health care sector. I bet they will do a better job at innovation than HHS or some other government department. Whether they merely support the existing insurance industry with consulting or expect to replace it entirely remains unclear.

Drug companies should expect these data innovators to be adept at negotiating prices based on patient outcomes. Verily and others will eventually be able to advise providers, payers, and patients which branded drugs to use. They may also be the ones to sell drugs to patients. No one expected Amazon to dominate the retail world 10 years ago. I would not bet against Verily, Amazon, or a new tech company to reinvent the whole health care delivery system. The world of 2028 will be significantly different in how we interact with payers and providers. Of course, if we get single payer government run healthcare then all bets are off as to innovation. Let’s hope the innovative tech giants get their chance first.

Bob Ehrlich


February 28, 2018 0

Last week the Departments of Health Human Services (HHS), Labor, and Treasury proposed a rule that would “expand the availability of short-term, limited-duration health insurance by allowing consumers to buy plans providing coverage for any period of less than 12 months, rather than the current maximum period of less than three months.” This will not only provide affordable coverage to Americans who may not have been able to afford current premiums and options, or lacked access to choices that properly matched their needs, but it will “increase competition, choice, and access to lower-cost healthcare options for Americans.”

While the purpose of these health plans was for temporary coverage, but due to their affordability, access to such plans “has become increasingly important as premiums have more than doubled between 2013 and 2017 in health plans on the Federal Health Insurance Exchange,” the news release stated. The short-term, limited-duration insurance does not have to comply with federal requirements for individual health insurance coverage.

Health and Human Services Secretary and former Lilly USA president Alex Azar stated: “Americans need more choices in health insurance so they can find coverage that meets their needs. The status quo is failing too many Americans who face skyrocketing costs and fewer and fewer choices. The Trump Administration is taking action so individuals and families have access to quality, affordable healthcare that works for them.”

admin


February 28, 2018 0

In the spring of 2018, Apple plans to premiere AC Wellness, independent medical centers for its employees and dependents offering concierge-like healthcare. As first reported by CNBC yesterday, Apple “quietly published a website, acwellness.com, with more details about its initiative and a careers page listing jobs.” While little information is currently available, AC Wellness’ website boasts that their Network will combine technology, high-quality care, and a unique patient experience to drive engagement and achieve exceptional health outcomes. The website also advertises for career opportunities. Positions to be filled include Health Partner, Physicians, Care Navigator, and Nurses, among others.

This initiative comes shortly after Tim Cook commented about Apple’s ability to make “significant contributions” to health care earlier this month during a shareholders meeting. Cook shared that the tech innovator is in a “great position”, being able to leverage its consumer-friendly approach, as reported by CNBC.

Apple has already been collaborating with the FDA to improve regulations on digital health products. Other coordinators announced last summer as a part of the FDA’s Pre-cert pilot program were Fitbit, Johnson & Johnson, Pear Therapeutics, Phosphorus, Roche, Samsung, Tidepool, and Verily. The work is a part of the Digital Health Innovation Action Plan.

admin


February 21, 2018 1

As a company whose products impact the lives of millions of people, many of them managing serious health conditions, we are aware of how societal trends have transformed the way people relate to their health and have evolved their expectations of companies like ours.

So when we decided to launch a new brand positioning, we not only wanted to build an identity that spanned specialty and generics and unified our businesses around the world after decades of acquisitions, but also one that positioned us as a trustworthy partner to the patients, caregivers and healthcare professionals we serve.

To look within and beyond our medicine cabinet with a fresh perspective, we got out of our laboratories and into the real world, asking questions and listening carefully to the answers. From 2015 to 2017, we talked to more than 21,000 patients, caregivers, and healthcare professionals in 20 countries. The simplest insights gained from this research have proved to be the most profound:

  • Few things matter more to people than their health, and they want to feel in control of their journey at every stage of life, both in terms of prevention and in the challenges of managing a disease. They use digital resources to seek out information they can understand from sources they can trust.
  • Consumers’ experience of service in other categories has created high expectations. They are looking for personalization, value, convenience, and relationships. Half of people want pharmaceutical companies to connect with them—online and on mobile—to provide on-demand resources and services.
  • Health means much more than diseases. We learned that people want a holistic experience that addresses their whole person: body, mind, and spirit. This includes health inputs like nutrition and medicine, health outputs like confidence and vitality, and long-term health outcomes like resilience and happiness.

These insights have proved vital as Teva has gone through an important transformation, unifying the company while also becoming simpler, leaner, and more agile. It’s not easy to form a new understanding of a company that’s been around since 1901, and launching a new brand during a restructuring isn’t necessarily intuitive. But our research helped us to understand that consumers expect us to support their health journeys, leveraging our experience to go beyond medicines to the effects of their conditions on their whole lives. And they also want to know about the company itself—insights about the character of our people, what we care about, and how we give back.

Teva's new branded advertising, website, exhibition booth, and packaging.

Our new brand identity emphasizes that Teva is warm, approachable, accessible, and modern—a company that not only makes high-quality products but also one that listens to the people it serves. Ever mindful of our financial situation, we used existing resources in new ways, focusing on evolving the most impactful touch points to people—packaging and digital—while taking advantage of portfolio optimization, regulatory requirements such as serialization, product launches, office moves, and planned events where possible. Through it all, we’ve focused on evolving our value proposition, incorporating storytelling into our digital content offering, and making our new brand a vehicle for unification and simplification.

We’re implementing the new global brand from the bottom up, through a hyperlocal implementation approach that goes market by market with a meticulous test-and-learn rollout grounded in data and insights. To build local relevance into a global framework, we are evolving our value proposition to reflect the nuances of each market, including our business model and portfolio; the local healthcare system; and the specific needs of that market’s consumers, patients, and healthcare professionals. We started with our own employees, soft-launching the brand internally in 2016 to assess the resonance and relevance of the new positioning in different cultures and healthcare systems. Since then we’ve launched in France, Russia, and Argentina, and are rolling out the new brand in Canada and the U.S. this month, with additional launches planned throughout 2018.

In the U.S., for example, where people are more likely to suffer from chronic issues (65% versus 60% globally), we’ve partnered with Mount Sinai Hospital to meet the needs of those with multiple chronic conditions. And in Canada, where 37% of people are caregivers—supporting loved ones who could not cope without them—we’ve teamed up with caregiver advocacy groups to better support that underserved population.

And to deliver the credible online health information that patients around the world are seeking, we’ve piloted a series of articles, videos, and podcasts with the help of Healthline and the Slate Media Group. In the coming months, we’ll introduce a branded portal—first to the U.S. and then to the rest of the world—as well as a documentary film demonstrating what it’s like to be a patient with chronic conditions.

Our research has shown that digital is a cost-effective, convenient, and preferred way for us to bring value to patients and caregivers through information and resources that go beyond medicine, looking at health conditions from the point of view of patients in the context of their lives—not in the context of symptoms and side effects—which is critical to delivering on our brand promise of helping them to live better days.

Beyond gathering valuable insights and information—and meeting a lot of interesting people—our research is helping us become a simpler and more patient-centered organization, aiming to increase the trust people have in us to support their health needs.

Click here to read Teva's news release about their new brand positioning and visual identity.

 

Iris Beck-Codner


February 13, 2018 0

DTC Perspectives, Inc., the leading conference, training and publishing company for the consumer marketing of pharmaceutical and healthcare products, is proud to announce its 10th annual class of inductees into the DTC Hall of Fame. The 2018 class will be honored live at an induction ceremony sponsored by PatientPoint, at the Sheraton Boston in Boston, MA as part of DTC Perspectives’ 2018 DTC National Conference. (Separate tickets are also available.)

“PatientPoint and I congratulate the 2018 DTC Hall of Fame inductees. Their extraordinary achievements in advancing the spectrum of patient communications has driven the industry forward, and for that, we are all grateful. We look forward to celebrating their accomplishments at the DTC National Conference.” Says Linda Ruschau, Chief Client Officer of PatientPoint.

This year’s inductees are:

Christine-Sakdalan-headshot-web

Christine Sakdalan
Vice President Marketing, Bone and Cardiovascular Business Unit
Amgen

Gary Scheiner headshot

Gary Scheiner
EVP, Chief Creative Officer
ghg | greyhealth group

Tatyana Tsinberg headshot

Tatyana Tsinberg
Vice President, Cross Therapeutic Area Brand Lead
Pfizer

180214_Cynthia-Rothbard0248---web

Cynthia Rothbard
EVP, Creative Director
FCB Health

The DTC Hall of Fame is designed to honor individuals who have demonstrated extraordinary achievement in the advancement of direct-to-consumer marketing. Industry-wide nominations are collected and then the final four inductees are determined by DTC Perspectives' executive and editorial teams.

“DTC marketing has been practiced successfully for more than twenty years and over this time it has grown to become a very important component of the pharmaceutical industry’s success,” says Bob Ehrlich, CEO of DTC Perspectives. “It is important to recognize those individuals who have shaped DTC advertising and significantly contributed to the communication of important healthcare information directly to patients.”

As part of the DTC National, the DTC Hall of Fame festivities include a cocktail party followed by a formal induction ceremony on April 18th presented by PatientPoint, with video tributes and live introductions from industry leaders, as well as an address by the Hall of Fame inductees. Each inductee is also profiled in the annual conference guide publication.

The DTC National is a “must-attend” event for pharmaceutical marketers, agency executives, media partners, market researchers, and solution providers looking to further advance patient communications. Please visit our website, http://www.dtc-national.com, for complete agenda information, available sponsorship and congratulatory opportunities, and additional details.

Celebrate with the Industry's Best

Congratulate the Hall of Fame inductees in-person and in our publications! DTC Perspectives offers reserved tables with seating for 10 at the Top 25/Hall of Fame and Advertising Awards ceremonies as well as congrats ads opportunities in our DTC Perspectives Magazine/DTC National Conference Guide, on our website, and in Email announcements. Click here to view awards packages and congratulate a Top Marketer/DTC Hall of Fame inductee today.

Print congrats ad deadline: Friday, March 2, 2017

Purchase Tables & Congrats Ads

admin